On top of strong efficacy data, Alder migraine med shows potential

Shares of Alder Therapeutics ($ALDR) spiked 55% when the company released promising Phase IIb study data of its intravenous candidate for treating migraines. While approval is the foremost topic on investor's minds at the moment, success in the commercial arena will require differentiation in light of promising efficacy data from a similar Phase IIb Teva ($TEVA) candidate; Eli Lilly ($LLY) and Amgen ($AMGN) are also in the game. Luckily, the company also posted strong Phase I results of a, you guessed it, drug delivery study, which indicated that intravenous, subcutaneous or intramuscular injection could enable a quarterly dosing strategy. In addition to longer intervals between drug administration, patients often prefer subcutaneous or intramuscular injections to intravenous infusions. Convenience is key when it comes to commercialization. More from FierceBiotech | Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.